Gut Leakage' in Dengue (GLiD)
Gut Leakage and Sonographic Abdominal Changes in Hospitalized Dengue Patients: an Observational Study
Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the development of medical counter measures because of the high risk of it causing a Public Health Emergency of Intenational Concern (PHEIC). Warning signs for severe dengue, associated with mortality, include gastrointestinal features including abdominal pain, vomiting, and diarrhoea. Multiple alterations may occur in in the gastrointestinal tract that could lead to damaging of the gastrointestinal wall and gut leakage, the translocation of gut metabolites into the bloodstream. Study team hypothesize that gut leakage initiates inflammatory processes underlying the further development of severe dengue, including features associated with plasma leakage.
This study aims to investigate intestinal barrier dysfunction (gut leakage) in dengue infection by detecting the translocation of gut-derived bacteria and their products (Lipopolysaccharides, LPS binding protein, sCD14, I-Fatty Acid Binding Protein) into the bloodstream. Study team will recruit hospitalized adult dengue patients (18 years and older) presenting with warning signs or severe disease in a tertiary care public hospital at Chattogram, Bangladesh. Circulating biomarkers indicative of gut permeability and microbial translocation will be measured to assess their presence and association with disease severity.
Abdominal ultrasonography will be performed to characterize gastrointestinal alterations and determine their correlation with biochemical markers of gut leakage and clinical severity. In addition, study team will analyze the gut bacteriome from stool/ rectal swab of these patients to explore whether dengue infection induces compositional changes in intestinal microbiota and whether such alterations are linked to gut leakage or disease progression.
연구 개요
상태
연구 유형
등록 (추정된)
연락처 및 위치
연구 장소
-
-
Chattogram Division
-
Chittagong, Chattogram Division, 방글라데시, 4203
- 모병
- Department of Medicine, Chittagong Medical College
-
연락하다:
- Rabiul Alam Md Erfan Uddin, FCPS
- 전화번호: +8801711129798
- 이메일: rubelerfan@gmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
Adult (≥18 years) male and non-pregnant female patients with confirmed dengue (positive NS1 antigen and/or IgM) admitted to the Department of Medicine, Chittagong Medical College Hospital will be recruited. Blood biomarkers will be collected at enrollment for all patients. Those initially classified as non-severe dengue will have no repeat sampling unless they progress to severe disease, in which case a second sample will be obtained within 24 hours. Serum ALT and blood culture will be performed on day 7 of illness. Stool samples will be collected on day 7 from 100 patients for gut microbiota analysis.
Additionally, 10 healthy adult participants (5 male, 5 female) will be recruited from patient attendants. They will undergo a single visit for baseline biomarker sampling and POCUS, serving as healthy controls for comparison.
설명
Inclusion Criteria:
Dengue participants
- Participant/ legally authorised representative willing and able to give informed consent for participation in the study.
- Male or Female, adults ≥18 years
- Diagnosed as a case of Dengue on the basis of clinical features and positive NS1 antigen and/or IgM dengue antibody
- Hospitalized in medicine or dengue ward in Chittagong Medical College Hospital.
- Enrolled within 24 hours of hospitalization.
Healthy participants
- Participant/ legally authorised representative willing and able to give informed consent for participation in the study.
- Male or Female, adults ≥18 years
- Clinically healthy with no acute or chronic illness
- Attendant of a dengue patient (not a patient)
Exclusion Criteria:
Dengue participants
- Unable to provide consent or participate in follow-up procedures
- Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (<3 months) major GI surgery.
- Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.
- Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.
- Pregnancy
Healthy participants
- Unable to provide consent
- Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (<3 months) major GI surgery.
- Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.
- Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.
- Pregnancy
- History of current or recent dengue or other arbo viral infection
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
Severe dengue
All enrolled dengue patients will have blood biomarkers at enrolment whether they present with non-severe or severe dengue.
If participant enrolled as non-severe and do not progress to severe dengue, they will be no second test for biomarkers but if they developed clinical feature of severity, a second biomarker sample will be collected within 24 hours of developing clinical severity.
S ALT and Blood culture will be performed on day 7 of illness for all dengue patients.
Stool will be collected on day 7 of illness from 100 patients for testing gut microbiota.
|
|
Non-severe dengue
All enrolled dengue patients will have blood biomarkers at enrolment whether they present with non-severe or severe dengue.
If participant enrolled as non-severe and do not progress to severe dengue, they will be no second test for biomarkers but if they developed clinical feature of severity, a second biomarker sample will be collected within 24 hours of developing clinical severity.
S ALT and Blood culture will be performed on day 7 of illness for all dengue patients.
Stool will be collected on day 7 of illness from 100 patients for testing gut microbiota.
|
|
Healthy individual
These participants will undergo only one study visit for baseline biomarker sampling, baseline POCUS and will not undergo follow-up.
Their results will serve as healthy control reference values for comparison with biomarker findings in dengue patients.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Level of gut leakage marker in blood and gastrointestinal findings in POCUS
기간: On enrollment, day of development of severity if non severe at enrolment, up to 28 days
|
On enrollment, day of development of severity if non severe at enrolment, up to 28 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Document clinical events occurred in dengue patients
기간: Through study completion, an average of 28 days
|
Demographic: Age, gender, BMI Clinical: respiratory rate, blood pressure, heart rate, ascites, pleural effusion, any major bleeding, GCS |
Through study completion, an average of 28 days
|
|
Document clinical events occurred in dengue patients
기간: Day of enrolment/ 4th or day 7 of illness
|
For mSOFA: SpO2, FiO2 |
Day of enrolment/ 4th or day 7 of illness
|
기타 결과 측정
결과 측정 |
기간 |
|---|---|
|
Level of I-FABP Level of LPS, Level of LBP, Level of sCD14, Positive Blood culture
기간: On enrollment in all cases, if clinical severity occur in initial non-severe group, 24 hours within developing severity
|
On enrollment in all cases, if clinical severity occur in initial non-severe group, 24 hours within developing severity
|
|
Alteration of gut microbiota
기간: Day seven of illness
|
Day seven of illness
|
|
Organ failure
기간: Through study completion, an average of 28 day
|
Through study completion, an average of 28 day
|
|
Development of shock
기간: Through study completion, an average of 28 day
|
Through study completion, an average of 28 day
|
|
Detectable fluid collection in abdomen, loss of haustration, loss of normal multi-layered appearance
기간: Baseline (within 24 hours of enrollment) and at the time of first development of clinical severity, assessed from enrollment until clinical severity occurs, hospital discharge, death, or up to 7 days of hospitalization, whichever occurs first.
|
Baseline (within 24 hours of enrollment) and at the time of first development of clinical severity, assessed from enrollment until clinical severity occurs, hospital discharge, death, or up to 7 days of hospitalization, whichever occurs first.
|
|
Measurement of gall bladder wall thickness, intestinal wall thickness
기간: Baseline (within 24 hours of enrollment) and at the time of first development of clinical severity, assessed from enrollment until clinical severity occurs, hospital discharge, death, or up to 7 days of hospitalization, whichever occurs first.
|
Baseline (within 24 hours of enrollment) and at the time of first development of clinical severity, assessed from enrollment until clinical severity occurs, hospital discharge, death, or up to 7 days of hospitalization, whichever occurs first.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- VIR26001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .